- Home
- LEXX vs VTVT Comparison
LEXX vs VTVT Comparison
Compare LEXX & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- VTVT
- Stock Information
- Founded
- LEXX 2004
- VTVT 2015
- Country
- LEXX Canada
- VTVT United States
- Employees
- LEXX N/A
- VTVT N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- VTVT Health Care
- Exchange
- LEXX Nasdaq
- VTVT Nasdaq
- Market Cap
- LEXX 39.1M
- VTVT 38.8M
- IPO Year
- LEXX N/A
- VTVT 2015
- Fundamental
- Price
- LEXX $1.84
- VTVT $13.76
- Analyst Decision
- LEXX Strong Buy
- VTVT Strong Buy
- Analyst Count
- LEXX 2
- VTVT 1
- Target Price
- LEXX $11.00
- VTVT $35.00
- AVG Volume (30 Days)
- LEXX 245.8K
- VTVT 8.5K
- Earning Date
- LEXX 01-10-2025
- VTVT 03-12-2025
- Dividend Yield
- LEXX N/A
- VTVT N/A
- EPS Growth
- LEXX N/A
- VTVT N/A
- EPS
- LEXX N/A
- VTVT N/A
- Revenue
- LEXX $496,923.00
- VTVT $1,000,000.00
- Revenue This Year
- LEXX $20.39
- VTVT N/A
- Revenue Next Year
- LEXX $113.25
- VTVT N/A
- P/E Ratio
- LEXX N/A
- VTVT N/A
- Revenue Growth
- LEXX 77.63
- VTVT 11011.11
- 52 Week Low
- LEXX $1.36
- VTVT $7.38
- 52 Week High
- LEXX $6.85
- VTVT $30.99
- Technical
- Relative Strength Index (RSI)
- LEXX 40.43
- VTVT 46.05
- Support Level
- LEXX $1.87
- VTVT $13.90
- Resistance Level
- LEXX $2.04
- VTVT $14.35
- Average True Range (ATR)
- LEXX 0.22
- VTVT 0.52
- MACD
- LEXX -0.02
- VTVT 0.04
- Stochastic Oscillator
- LEXX 40.74
- VTVT 38.59
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.